The European Medicines Agency is recommending that the world’s leading malaria vaccine be licensed even though it is only about 30 percent effective and that protection fades over time. In a statement published on Friday, the agency said it had “adopted a positive scientific opinion” for the vaccine’s use outside the European Union, a regulatory process that helps speed new medicines to the market.

Click here to read original article